Bcr-Abl

Bcr-Abl tyrosine-kinase inhibitors (TKI) are the first-line therapy for most patients with chronic myelogenous leukemia (CML). More than 90% of CML cases are caused by a chromosomal abnormality that results in the formation of a so-called Philadelphia chromosome. This abnormality is a consequence of fusion between the Abelson (Abl) tyrosine kinase gene at chromosome 9 and the break point cluster (Bcr) gene at chromosome 22, resulting in a chimeric oncogene (Bcr-Abl) and a constitutively active Bcr-Abl tyrosine kinase that has been implicated in the pathogenesis of CML. Compounds have been developed to selectively inhibit the tyrosine kinase.

Bcr-Abl Inhibitors & Activators

Adaphostin
(NSC 680410) Cat. No.: HY-103275

Adaphostin (NSC 680410), the adamantyl ester of AG957, is a potent **p210**$^{bcr/abl}$ inhibitor (IC_{50}=14 μM). Adaphostin induces apoptosis in T-lymphoblastic human leukemia cell lines (IC_{50} ranging from 17 to 216 nM).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

AG957
(Tyrphostin AG957; NSC 654705) Cat. No.: HY-117718

AG957 (Tyrphostin AG957;NSC 654705) is a tyrosine kinase inhibitor with anti-**BCR/ABL** tyrosine kinase activity. AG957 is a **bcr/abl** kinase inhibitor with an IC_{50} of 2.9 μM for **p210**$^{bcr/abl}$ autokinase activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Asciminib
(ABL001) Cat. No.: HY-104010

Asciminib (ABL001) is a potent and selective allosteric **BCR-ABL1** inhibitor, which inhibits Ba/F3 cells grown with an IC_{50} of 0.25 nM.



Purity: 99.78%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

AST 487
(NVP-AST 487) Cat. No.: HY-15002

AST 487 is a **RET** kinase inhibitor with IC_{50} of 880 nM, inhibits RET autophosphorylation and activation of downstream effectors, also inhibits **Flt-3** with IC_{50} of 520 nM.



Purity: 99.20%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

AT9283
Cat. No.: HY-50514

AT9283 is a multi-targeted kinase inhibitor with potent activity against **Aurora A/B**, **JAK2/3**, **Abl (T315I)** and **Flt3** (IC_{50}s ranging from 1 to 30 nM). AT9283 inhibits growth and survival of multiple solid tumors in vitro and in vivo.



Purity: 99.70%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 50 mg, 100 mg

AZD0424
Cat. No.: HY-112314

AZD0424 is an orally active, and dual selective **Src/Abl** kinase inhibitor with potential antineoplastic activity. AZD0424 induces **apoptosis** and cell cycle arrest in lymphoma cells.



Purity: >98%
Clinical Data: Phase 1
Size: 1 mg, 5 mg

Bafetinib
(INNO-406; NS-187) Cat. No.: HY-50868

Bafetinib is a potent and orally active **Lyn/Bcr-Abl** tyrosine kinase inhibitor. Bafetinib augments the activities of several proapoptotic Bcl-2 homology (BH)3-only proteins (Bim, Bad, Bmf and Bik) and induces apoptosis in Ph^+ leukemia cells via Bcl-2 family-regulated intrinsic apoptosis pathway.



Purity: 99.76%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

BCR-ABL-IN-1
Cat. No.: HY-100314

BCR-ABL-IN-1 is an inhibitor of **BCR-ABL** tyrosine kinase, with a **pIC**$_{50}$ of 6.46, and may be used in the research of chronic myelogenous leukemia.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

BCR-ABL-IN-2
Cat. No.: HY-18819

BCR-ABL-IN-2 is an inhibitor of **BCR-ABL1** tyrosine kinase, with **IC**$_{50}$**s** of 57 nM, 773 nm for $ABL1^{native}$ and $ABL1^{T315I}$, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

BCR-ABL-IN-3
Cat. No.: HY-136526

BCR-ABL-IN-3 is a potent and irreversible **Bcr-Abl** inhibitor with an IC_{50} of ≤100 nM for $Ba/F_3Bcr\text{-}Abl^{T315I}$. BCR-ABL-IN-3 has anti-cancer activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

BCR-ABL-IN-4

Cat. No.: HY-142922

BCR-ABL-IN-4 is a **BCR-ABL** inhibitor with anticancer effects. BCR-ABL-IN-4 inhibits the cancer cell growth with IC_{50} values of 0.67 nM and 16 nM for K562 cells and BCR-ABL T315I transfected Ba/F3 cells, respectively (WO2021143927A1; compound 11).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Bosutinib

(SKI-606)

Cat. No.: HY-10158

Bosutinib is a dual **Src/Abl** inhibitor with IC_{50}s of 1.2 nM and 1 nM, respectively.



Purity: 99.96%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 200 mg

Bosutinib D8

(SKI-606 D8)

Cat. No.: HY-10158S

Bosutinib D8 (SKI-606 D8) is a deuterium labeled Bosutinib. Bosutinib is a dual **Src/Abl** inhibitor with IC_{50}s of 1.2 nM and 1 nM, respectively.



Purity: ≥99.0%
Clinical Data: No Development Reported
Size: 1 mg

c-ABL-IN-2

Cat. No.: HY-146527

c-ABL-IN-2 is a potent inhibitor of **c-Abl**. Activation of c-Abl has been implicated in various diseases, notably cancer.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Cenisertib

(AS-703569; R-763)

Cat. No.: HY-13072

Cenisertib (AS-703569) is an ATP-competitive multi-kinase inhibitor that blocks the activity of **Aurora-kinase-A/B, ABL1, AKT, STAT5 and FLT3**.



Purity: 99.64%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

CHMFL-ABL-039

Cat. No.: HY-126143

CHMFL-ABL-039 is a type II native **ABL** kinase and drug-resistant V299L mutant **BCR-ABL** inhibitor with the IC_{50}s of 7.9 nM and 27.9 nM, respectively. CHMFL-ABL-039 is used in the research of chronic myeloid leukemia.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

CHMFL-ABL-121

Cat. No.: HY-119370

CHMFL-ABL-121 is a highly potent type II **ABL kinase** inhibitor with IC_{50}s of 2 nM and 0.2 nM against purified inactive ABL wt and T315I kinase protein, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

CHMFL-ABL/KIT-155

(CHMFL-ABL-KIT-155)

Cat. No.: HY-101034

CHMFL-ABL/KIT-155 (CHMFL-ABL-KIT-155; compound 34) is a highly potent and orally active **type II ABL/c-KIT** dual kinase inhibitor (IC_{50}s of 46 nM and 75 nM, respectively), and it also presents significant inhibitory activities to BLK (IC_{50}=81 nM), CSF1R (IC_{50}=227 nM), DDR1 (IC_{50}=116 nM),...



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

CT-721

Cat. No.: HY-108704

CT-721 is a potent and time-dependent **Bcr-Abl kinase** inhibitor with an IC_{50} of 21.3 nM for wild-type Bcr-Abl kinase, and possesses anti-chronic myeloid leukemia (CML) activities.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

CZC-8004

(CZC-00008004)

Cat. No.: HY-111138

CZC-8004 is a pan-kinase inhibitor and binds a range of tyrosine kinases, including **ABL** kinase.



Purity: 99.61%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg

Dasatinib

(BMS-354825) Cat. No.: HY-10181

Dasatinib (BMS-354825) is a highly potent, ATP competitive, orally active dual **Src/Bcr-Abl** inhibitor with potent antitumor activity. The K_is are 16 pM and 30 pM for Src and Bcr-Abl, respectively.



Purity: 99.85%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 200 mg, 500 mg

Dasatinib hydrochloride

(BMS-354825 hydrochloride) Cat. No.: HY-10181A

Dasatinib (BMS-354825) hydrochloride is a highly potent, ATP competitive, orally active dual **Src/Bcr-Abl** inhibitor with potent antitumor activity. The K_is are 16 pM and 30 pM for Src and Bcr-Abl, respectively.



Purity: 98.86%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 200 mg, 500 mg

Dasatinib monohydrate

(BMS-354825 monohydrate) Cat. No.: HY-10181B

Dasatinib (BMS-354825) monohydrate is a highly potent, ATP competitive, orally active dual **Src/Bcr-Abl** inhibitor with potent antitumor activity. The K_is are 16 pM and 30 pM for Src and Bcr-Abl, respectively.



Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

Dasatinib-d8

(BMS-354825-d8) Cat. No.: HY-10181S

Dasatinib D8 is a deuterium labeled Dasatinib. Dasatinib is a dual Bcr-Abl and Src family tyrosine kinase inhibitor.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

DB07107

Cat. No.: HY-123390

DB07107 is a potent drug resistant **T315I mutant Bcr-Abl tyrosine kinase** inhibitor. DB07107 is also a potent **Akt1** inhibitor with an IC_{50} value of 360 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Debio 0617B

Cat. No.: HY-108417

Debio 0617B, a multi-kinase inhibitor, reduces maintenance and self-renewal of primary human AML $CD34^+$ stem/progenitor cells.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Degrasyn

(WP1130) Cat. No.: HY-13264

Degrasyn (WP1130) is a cell-permeable **deubiquitinase (DUB)** inhibitor, directly inhibiting DUB activity of USP9x, USP5, USP14, and UCH37. Degrasyn has been shown to downregulate the antiapoptotic proteins **Bcr-Abl** and **JAK2**.



Purity: 99.70%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

DPH

Cat. No.: HY-12070

DPH is a potent cell permeable **c-Abl** activator, which displays potent enzymatic and cellular activity in stimulating c-Abl activation. .



Purity: 99.20%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg

Flumatinib

(HHGV678) Cat. No.: HY-13904

Flumatinib (HHGV678) is an orally available, selective inhibitor of **Bcr-Abl**. Flumatinib inhibits **c-Abl**, **PDGFRβ** and **c-Kit** with IC_{50}s of 1.2 nM, 307.6 nM and 665.5 nM, respectively.



Purity: 99.94%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Flumatinib mesylate

(HHGV678 mesylate) Cat. No.: HY-13905

Flumatinib mesylate (HHGV678 mesylate) is an orally available, selective inhibitor of **Bcr-Abl**. Flumatinib mesylate inhibits **c-Abl**, **PDGFRβ** and **c-Kit** with IC_{50}s of 1.2 nM, 307.6 nM and 665.5 nM, respectively.



Purity: 99.97%
Clinical Data: Phase 4
Size: 10 mM × 1 mL, 500 mg

Flumatinib-d3

(HHGV678-d3)

Cat. No.: HY-13904S

Flumatinib-d3 is deuterium labeled Flumatinib. Flumatinib (HHGV678) is an orally available, selective inhibitor of Bcr-Abl. Flumatinib inhibits c-Abl, PDGFRβ and c-Kit with IC50s of 1.2 nM, 307.6 nM and 665.5 nM, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

GMB-475

Cat. No.: HY-125834

GMB-475 is a degrader of **BCR-ABL1** tyrosine kinase based on PROTAC, overcoming BCR-ABL1-dependent drug resistance. GMB-475 targets BCR-ABL1 protein and recruits the E3 ligase **Von Hippel Lindau** (VHL), resulting in ubiquitination and subsequent degradation of the oncogenic fusion protein.



Purity: 99.20%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

GNF-2

Cat. No.: HY-11007

GNF-2 is a highly selective, allosteric, non-ATP competitive inhibitor of **Bcr-Abl**. GNF-2 inhibits Ba/F3.p210 proliferation with an IC_{50} of 138 nM .



Purity: 98.73%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

GNF-5

Cat. No.: HY-15738

GNF-5, an analogue of GNF-2 with improved pharmacokinetic properties, is a selective non-ATP competitive inhibitor of Bcr-Abl with an IC50 value of 0.22±0.1 uM (Wild type Abl).



Purity: 99.42%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

GNF-7

Cat. No.: HY-10943

GNF-7 is a multikinase inhibitor. GNF-7 is a **Bcr-Abl** inhibitor, with IC_{50}s of 133 nM and 61 nM for Bcr-Abl^{WT} and Bcr-Abl^{T315I}, respectively.



Purity: 98.93%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

GZD856

Cat. No.: HY-101489

GZD856 formic is a potent and orally active **PDGFRα/β** inhibitor, with IC_{50}s of 68.6 and 136.6 nM, respectively. GZD856 formic is also a **Bcr-Abl^{T315I}** inhibitor, with IC_{50}s of 19.9 and 15.4nM for native Bcr-Abl and the T315I mutant. GZD856 formic has antitumor activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

GZD856 formic

Cat. No.: HY-101489A

GZD856 formic is a potent and orally active **PDGFRα/β** inhibitor, with IC_{50}s of 68.6 and 136.6 nM, respectively. GZD856 formic is also a **Bcr-Abl^{T315I}** inhibitor, with IC_{50}s of 19.9 and 15.4nM for native Bcr-Abl and the T315I mutant. GZD856 formic has antitumor activity.



Purity: 98.06%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

HG-7-85-01

Cat. No.: HY-15814

HG-7-85-01 is a type II ATP competitive inhibitor of wild-type and gatekeeper mutations forms of **Bcr-Abl**, **PDGFRα**, **Kit**, and **Src kinases**.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

IHMT-TRK-284

Cat. No.: HY-146697

IHMT-TRK-284 (Compound 34) is a potent, orally active **type II TRK kinase** inhibitor with IC_{50} values of 10.5, 0.7, and 2.6 nM to **TRKA, B**, and **C** respectively. IHMT-TRK-284 displays great selectivity profile in the kinome and good in vivo antitumor efficacies.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Imatinib

(STI571; CGP-57148B)

Cat. No.: HY-15463

Imatinib (STI571) is an orally bioavailable tyrosine kinases inhibitor that selectively inhibits **BCR/ABL**, **v-Abl**, **PDGFR** and **c-kit** kinase activity.



Purity: 99.54%
Clinical Data: Launched
Size: 10 mM × 1 mL, 200 mg, 500 mg, 1 g, 5 g

Imatinib D4

(STI571 D4; CGP-57148B D4) Cat. No.: HY-15463S1

Imatinib D4 (STI571 D4) is a deuterium labeled Imatinib (STI571). Imatinib is an orally bioavailable tyrosine kinases inhibitor that selectively inhibits BCR/ABL, v-Abl, PDGFR and c-kit kinase activity.



Purity: ≥99.0%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Imatinib Mesylate

(STI571 Mesylate; CGP-57148B Mesylate) Cat. No.: HY-50946

Imatinib Mesylate (STI571 Mesylate) is a tyrosine kinases inhibitor that inhibits **c-Kit**, **Bcr-Abl**, and **PDGFR** (IC_{50}=100 nM) tyrosine kinases.



Purity: 99.91%
Clinical Data: Launched
Size: 10 mM × 1 mL, 200 mg, 500 mg, 1 g, 5 g

Imatinib-d8

(STI571-d8; CGP-57148B-d8) Cat. No.: HY-15463S

Imatinib D8 (STI571 D8) is a deuterium labeled Imatinib (STI571). Imatinib is an orally bioavailable tyrosine kinases inhibitor that selectively inhibits BCR/ABL, v-Abl, PDGFR and c-kit kinase activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg

KW-2449

Cat. No.: HY-10339

KW-2449 is a multi-targeted kinase inhibitor of **FLT3**, **ABL**, **ABL**^{T315I} and **Aurora kinase** with IC_{50}s of 6.6, 14, 4 and 48 nM, respectively.



Purity: 99.85%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

LXH254

Cat. No.: HY-112089

LXH254 is a potent, selective, orally active, type II **BRAF** and **CRAF** inhibitor, with IC_{50} values of 0.072 and 0.21 nM against CRAF and BRAF, respectively.



Purity: 99.95%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg

Lyn-IN-1

(Bafetinib analog) Cat. No.: HY-12039

Lyn-IN-1 (Bafetinib analog) is a potent and selective dual Bcr-Abl/Lyn inhibitor, extracted from patent WO2014169128A1.



Purity: 99.58%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

ML786 dihydrochloride

Cat. No.: HY-14979A

ML786 dihydrochloride is a potent and orally bioavailable **Raf** inhibitor, with IC_{50}s of 2.1, 4.2, and 2.5 nM for ^{V600E}**ΔB-Raf**, **wt B-Raf**, and **C-Raf**, respectively. ML786 dihydrochloride also inhibits **Abl-1**, **DDR2**, **EPHA2**, **KDR**, and **RET** (IC_{50}=<0.5, 7.0, 11, 6.2, 0.8 nM).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Multi-kinase inhibitor 1

Cat. No.: HY-103032

Multi-kinase inhibitor 1 is a potent **multi-kinase** inhibitor. Multi-kinase inhibitor 1 has the potential for diseases or disorders associated with abnormal or deregulated tyrosine kinase activity, particularly diseases associated with the activity of **PDGF-R**, **c-Kit** and **Bcr-abl**.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Nilotinib

(AMN107) Cat. No.: HY-10159

Nilotinib is an orally available **Bcr-Abl** tyrosine kinase inhibitor with antineoplastic activity.



Purity: 99.96%
Clinical Data: Launched
Size: 100 mg, 200 mg, 500 mg

Nilotinib monohydrochloride monohydrate

(AMN107 monohydrochloride monohydrate) Cat. No.: HY-10159A

Nilotinib monohydrochloride monohydrate is a second generation tyrosine kinase inhibitor (TKI), is significantly potent against **BCR-ABL**, and is active against many BCR-ABL mutants.



Purity: 99.89%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 200 mg, 500 mg

Nilotinib-d3

Cat. No.: HY-132549S

Nilotinib-d3 (AMN107-d3) is the deuterium labeled Nilotinib. Nilotinib is an orally available **Bcr-Abl** tyrosine kinase inhibitor with antineoplastic activity.



Purity: >98%
Clinical Data:
Size: 1 mg, 10 mg

Nilotinib-d6

(AMN107-d6)

Cat. No.: HY-10159S

Nilotinib D6 (AMN107 D6) is a deuterium labeled Nilotinib. Nilotinib is an orally available **Bcr-Abl** tyrosine kinase inhibitor with antineoplastic activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Nocodazole

(Oncodazole; R17934)

Cat. No.: HY-13520

Nocodazole (Oncodazole) is a rapidly-reversible inhibitor of **microtubule**. Nocodazole binds to β-tubulin and disrupts microtubule assembly/disassembly dynamics, which prevents mitosis and induces apoptosis in tumor cells.



Purity: 99.66%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Olverembatinib

(GZD824; HQP1351)

Cat. No.: HY-15666

Olverembatinib (GZD824) is a potent and orally active pan-**Bcr-Abl** inhibitor. Olverembatinib potently inhibits a broad spectrum of Bcr-Abl mutants. Olverembatinib strongly inhibits native Bcr-Abl and Bcr-Abl^{T315I} with **IC_{50}**s of 0.34 nM and 0.68 nM, respectively.



Purity: 99.78%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg

Olverembatinib dimesylate

(GZD824 dimesylate; HQP1351 dimesylate)

Cat. No.: HY-15666A

Olverembatinib (GZD824) dimesylate is a potent and orally active pan-**Bcr-Abl** inhibitor. Olverembatinib dimesylate potently inhibits a broad spectrum of Bcr-Abl mutants.



Purity: 99.81%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg

ON 146040

Cat. No.: HY-12338

ON 146040 is a potent **PI3Kα** and **PI3Kδ** (**IC_{50}**≈14 and 20 nM, respectively) inhibitor. ON 146040 also inhibits **Abl1** (**IC_{50}**<150 nM).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PD173955

Cat. No.: HY-10395

PD173955 is src family-selective tyrosine kinase inhibitor with IC50 of ~22 nM for Src, Yes and Abl kinase; less potent for FGFRα and no activity on InsR and PKC.



Purity: 99.12%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

PD180970

Cat. No.: HY-103274

PD180970 is a highly potent and ATP-competitive **p210$^{Bcr-Abl}$ kinase** inhibitor, with an **IC_{50}** of 5 nM for inhibiting the autophosphorylation of **p210$^{Bcr-Abl}$**. PD180970 also inhibits **Src** and **KIT** kinase with **IC_{50}**s of 0.8 nM and 50 nM, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

Pivanex

(AN-9; Pivalyloxymethyl butyrate)

Cat. No.: HY-120508

Pivanex (AN-9), a derivative of Butyric acid, is an orally active **HDAC** inhibitor. Pivanex down-regulates **bcr-abl** protein and enhances **apoptosis**. Pivanex has antimetastic and antiangiogenic properties.



Purity: >98%
Clinical Data: Phase 2
Size: 1 mg, 5 mg

Ponatinib

(AP24534)

Cat. No.: HY-12047

Ponatinib (AP24534) is an orally active multi-targeted kinase inhibitor with **IC_{50}**s of 0.37 nM, 1.1 nM, 1.5 nM, 2.2 nM, and 5.4 nM for **Abl**, **PDGFRα**, **VEGFR2**, **FGFR1**, and **Src**, respectively.



Purity: 99.43%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Ponatinib hydrochloride

(AP24534 hydrochloride) Cat. No.: HY-108766

Ponatinib (AP24534) hydrochloride is a hydrochloride of ponatinib. Ponatinib is an orally active multi-targeted kinase inhibitor with IC_{50}s of 0.37 nM, 1.1 nM, 1.5 nM, 2.2 nM, and 5.4 nM for **Abl**, **PDGFRα**, **VEGFR2**, **FGFR1**, and **Src**, respectively.



Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

Ponatinib-d8

(AP24534-d8) Cat. No.: HY-12047S

Ponatinib D8 (AP24534 D8) is a deuterium labeled Ponatinib. Ponatinib (AP24534) is an orally active multi-targeted kinase inhibitor with IC_{50}s of 0.37 nM, 1.1 nM, 1.5 nM, 2.2 nM, and 5.4 nM for **Abl**, **PDGFRα**, **VEGFR2**, **FGFR1**, and **Src**, respectively.



Purity: 98.44%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PROTAC BCR-ABL1 ligand 1

Cat. No.: HY-130297

PROTAC BCR-ABL1 ligand 1, compound GMB-475, is the ligand of PROTAC that allosterically targets **BCR-ABL1** protein and recruits the E3 ligase Von Hippel-Lindau, resulting in ubiquitination and subsequent degradation of BCR-ABL1.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Radotinib-d6

Cat. No.: HY-15728S

Radotinib-d6 is deuterium labeled Radotinib.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Rebastinib

(DCC-2036) Cat. No.: HY-13024

Rebastinib (DCC-2036) is an orally active, non-ATP-competitive **Bcr-Abl** inhibitor for **Abl1^{WT}** and **Abl1^{T315I}** with IC_{50}s of 0.8 nM and 4 nM, respectively. Rebastinib also inhibits SRC, KDR, FLT3, and Tie-2, and has low activity to seen towards c-Kit.



Purity: 99.91%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

S116836

Cat. No.: HY-123450

S116836, a potent, orally active **BCR-ABL** tyrosine kinase inhibitor, blocks both wild-type as well as T315I Bcr-Abl.



Purity: 99.60%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

SIAIS178

Cat. No.: HY-128756

SIAIS178 is a potent and selective **BCR-ABL** degrader based on PROTAC technology with an IC_{50} of 24 nM. SIAIS178 causes effective degradation of BCR-ABL protein by recruiting **Von Hippel-Lindau** (VHL) E3 ubiquitin ligase. SIAIS178 has anticancer activity.



Purity: 99.48%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

SNIPER(ABL)-013

Cat. No.: HY-111860

SNIPER(ABL)-013, conjugating GNF5 (ABL inhibitor) to Bestatin (**IAP** ligand) with a linker, induces the reduction of **BCR-ABL** protein with a DC_{50} of 20 μM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

SNIPER(ABL)-015

Cat. No.: HY-111854

SNIPER(ABL)-015, conjugating GNF5 (ABL inhibitor) to MV-1 (**IAP** ligand) with a linker, induces the reduction of **BCR-ABL** protein with a DC_{50} of 5 μM .



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

SNIPER(ABL)-019

Cat. No.: HY-111873

SNIPER(ABL)-019, conjugating Dasatinib (ABL inhibitor) to MV-1 (**IAP** ligand) with a linker, induces the reduction of **BCR-ABL** protein with a DC_{50} of 0.3 μM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

SNIPER(ABL)-020

Cat. No.: HY-111872

SNIPER(ABL)-020, conjugating Dasatinib (ABL inhibitor) to Bestatin (**IAP** ligand) with a linker, induces the reduction of **BCR-ABL** protein.



Purity: 99.44%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg

SNIPER(ABL)-024

Cat. No.: HY-111861

SNIPER(ABL)-024, conjugating GNF5 (ABL inhibitor) to LCL161 derivative (**IAP** ligand) with a linker, induces the reduction of **BCR-ABL** protein with a DC_{50} of 5μM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

SNIPER(ABL)-033

Cat. No.: HY-111871

SNIPER(ABL)-033, conjugating HG-7-85-01 (ABL inhibitor) to LCL161 derivative (**IAP** ligand) with a linker, induces the reduction of **BCR-ABL** protein with a DC_{50} of 0.3 μM.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

SNIPER(ABL)-039

Cat. No.: HY-111874

SNIPER(ABL)-039, conjugating Dasatinib (ABL inhibitor) to LCL161 derivative (**IAP** ligand) with a linker, induces the reduction of **BCR-ABL** protein with a DC_{50} of 10 nM. IC_{50}s are 0.54 nM, 10 nM, 12 nM, and 50 nM for **ABL**, cIAP1, cIAP2, XIAP, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

SNIPER(ABL)-044

Cat. No.: HY-111862

SNIPER(ABL)-044, conjugating HG-7-85-01 (ABL inhibitor) to Bestatin (**IAP** ligand) with a linker, induces the reduction of **BCR-ABL** protein with a DC_{50} of 10 μM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

SNIPER(ABL)-047

Cat. No.: HY-111863

SNIPER(ABL)-047, conjugating HG-7-85-01 (ABL inhibitor) to MV-1 (**IAP** ligand) with a linker, induces the reduction of **BCR-ABL** protein with a DC_{50} of 2 μM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

SNIPER(ABL)-049

Cat. No.: HY-111851

SNIPER(ABL)-049, conjugating Imatinib (ABL inhibitor) to Bestatin (**IAP** ligand) with a linker, induces the reduction of **BCR-ABL** protein with a DC_{50} of 100 μM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

SNIPER(ABL)-050

Cat. No.: HY-111858

SNIPER(ABL)-050, conjugating Imatinib (ABL inhibitor) to MV-1 (**IAP** ligand) with a linker, induces the reduction of **BCR-ABL** protein.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

SNIPER(ABL)-058

Cat. No.: HY-111859

SNIPER(ABL)-058, conjugating Imatinib (ABL inhibitor) to LCL161 derivative (**IAP** ligand) with a linker, induces the reduction of **BCR-ABL** protein with a DC_{50} of 10 μM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Vodobatinib

(K0706)

Cat. No.: HY-137460

Vodobatinib (K0706) is a potent, third generation and orally active **Bcr-Abl1 tyrosine kinase** inhibitor with an IC_{50} of 7 nM. Vodobatinib exhibits activity against most BCR-ABL1 point mutants, and has no activity against BCR-ABL1T315I.



Purity: 98.98%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

XL228

Cat. No.: HY-15749

XL228 is a multi-targeted tyrosine kinase inhibitor with IC_{50}s of 5, 3.1, 1.6, 6.1, 2 nM for **Bcr-Abl**, **Aurora A**, **IGF-1R**, **Src** and **Lyn**, respectively.



Purity: 99.58%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg